Results 81 to 90 of about 2,230 (120)

People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu. [PDF]

Sci Rep
Cammarata-Mouchtouris A, Giraldo DM, Collins GL, Parrilla MM, Kim SO, Mansour S, Giacalone VD, Cottrill KA, Tirouvanziam R, Chandler JD.   +9 more
europepmc   +1 more source

Quality-by-Design-Driven RP-HPLC Method Development and Validation for Impurity Analysis of Elexacaftor, a Cystic Fibrosis Drug, with LC-MS/MS-Based Degradant Identification. [PDF]

ACS Omega
Raghupathi JK, Vemuri DK, Ali SM, Polisetti VK, Gundla R, Kowtharapu LP, Ramachandran D, Katari NK.   +7 more
europepmc   +1 more source

The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants. [PDF]

Eur Respir J
Drai C, van der Woude HJ, Lexmond AJ, van den Hoorn T, Mol PGM, Leacy FP, Przybyszewska A, Sepodes B, Castelnovo T.   +8 more
europepmc   +1 more source

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes. [PDF]

Gastro Hep Adv
Naimimohasses S, Ray A, Tan E, Wiggins A, Hasjim BJ, Chen S, Bhat M.   +6 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source

Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis. [PDF]

Endocr Connect
Edlund A, Lindberg U, Fagher K, Påhlman LI.   +3 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start. [PDF]

Am J Respir Crit Care Med
Selvadurai H.
europepmc   +1 more source

Cutaneous and Ocular Rosacea Associated with Elexacaftor, Tezacaftor and Ivacaftor, A Treatment for Cystic Fibrosis: A Case Report. [PDF]

J Pediatr Clin Pract
Piednoir A, Troussier F, Descamps M, Lagarce L, Martin L.   +4 more
europepmc   +1 more source

Modulation of host inflammatory pathways by <i>Pseudomonas aeruginosa</i> extracellular vesicles in cystic fibrosis: impact of pulmonary exacerbation and elexacaftor-tezacaftor-ivacaftor treatment. [PDF]

Front Immunol
Said M, Burrell A, Harmon B, Krohmaly KI, Mazur M, Solomon GM, Hahn A.   +6 more
europepmc   +1 more source

Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis. [PDF]

J Cosmet Dermatol
Smith AD, Lyons CE, Somerville L, Flowers RH, Kaplan E, Albon D.   +5 more
europepmc   +1 more source